Prelude Highlights Continued Strength of Discovery Engine at 2024 AACR Annual Meeting
09 avr. 2024 16h35 HE
|
Prelude Therapeutics, Inc.
Highly selective oral SMARCA2 degrader, PRT7732, shows robust anti-tumor activity in vivo as monotherapy and in combination with chemotherapy, at well-tolerated doses Potentially best-in-class CDK9...
Transgene et NEC présentent les premiers signes de bénéfice clinique de leur vaccin individualisé contre le cancer, TG4050, dans les cancers de la tête et du cou à l’AACR 2024
09 avr. 2024 11h45 HE
|
Transgene S.A.
Les nouvelles données immunologiques de Phase I confirment la forte immunogénicité de TG4050 dans le traitement adjuvant des cancers de la tête et du cou.Tous les patients traités sont encore en...
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
09 avr. 2024 11h45 HE
|
Transgene S.A.
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of...
iOmx Therapeutics to present new data on lead programs and I/O target screening platform at AACR 2024
03 avr. 2024 04h00 HE
|
iOmx Therapeutics AG
OMX-0407: clinical-stage, spectrum selective SIK kinase inhibitor with dual effect on tumor growth and immune evasionIOMX-0675: best-in-class antibody targeting immunosuppressive receptors LILRB1...
浩鼎將在 AACR 2024 年會 發表四篇論文
18 mars 2024 05h00 HE
|
OBI Pharma Inc.
台灣台北電, March 18, 2024 (GLOBE NEWSWIRE) -- 台灣浩鼎生技（4174）旗下自行開發的抗TROP2抗體藥物複合體（ADC）OBI-992，臨床前數據證明，它在多種動物實驗模式均顯示高效的抗腫瘤活性、優異的藥物動力學表現，和良好的安全性，具有發展為同類最佳抗TROP2...
浩鼎将在 AACR 2024 年会 发表四篇论文
18 mars 2024 05h00 HE
|
OBI Pharma Inc.
台湾台北电, March 18, 2024 (GLOBE NEWSWIRE) -- 台湾浩鼎生技（4174）旗下自行开发的抗TROP2抗体药物复合体（ADC）OBI-992，临床前数据证明，它在多种动物实验模式均显示高效的抗 肿瘤活性、优异的药物动力学表现，和良好的安全性，具有发展为同类最佳抗TROP2 ADC的潜力。...
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platform
18 mars 2024 05h00 HE
|
OBI Pharma Inc.
TAIPEI, Taiwan, March 18, 2024 (GLOBE NEWSWIRE) -- OBI Pharma, Inc. (TPEx: 4174) today announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate (ADC)....
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
08 mars 2024 08h00 HE
|
Onconova Therapeutics, Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
Cyclacel Pharmaceuticals Announces Preclinical Proof-of-Concept Data for Fadraciclib to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2024
07 mars 2024 09h15 HE
|
Cyclacel
BERKELEY HEIGHTS, N.J., March 07, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing...
Transgene présentera de nouvelles données sur son vaccin individualisé TG4050 à l’AACR 2024
06 mars 2024 01h30 HE
|
Transgene S.A.
Présentation d’un poster contenant de nouvelles donnéesde l’essai randomisé de Phase I de TG4050 dans les cancers de la tête et du cou Strasbourg, France, le 06 mars 2023, 7 h 30 — Transgene...